Galeterone Shows Promising Results In Castration-Resistant Prostate Cancer

Galeterone Shows Promising Results In Castration-Resistant Prostate Cancer
shutterstock_231755443Recent results from a clinical study (ARMOR2) assessing the anti-cancer drug galeterone, revealed it could successfully lower prostate-specific antigen (PSA) levels in patients who suffer from castration-resistant prostate cancer (CRPC). The data was presented by associate professor Mary-Ellen Taplin, of the Dana-Farber Cancer Institute during the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. “Recent data have shown that a variant of the androgen receptor called AR-V7, found in tumour cells circulating in the blood of patients with metastatic CRPC, predicted resistance to treatment with enzalutamide and abiraterone,” Prof. Taplin stated. “Indeed, we believe AR-V7 and other, related variants are a mechanism of resistance in this disease and patients who have them may have a poorer prognosis.” Galeterone has the capacity to inhibit the androgen receptor signaling pathways, which are directly linked to CRPC progression. During this Phase II clinical study, different clinical cente
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *